-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Earnings are growing at Kangji Medical Holdings (HKG:9997) but shareholders still don't like its prospects
Earnings are growing at Kangji Medical Holdings (HKG:9997) but shareholders still don't like its prospects
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in Kangji Medical Holdings Limited (HKG:9997) have tasted that bitter downside in the last year, as the share price dropped 51%. That's well below the market decline of 23%. Because Kangji Medical Holdings hasn't been listed for many years, the market is still learning about how the business performs. Furthermore, it's down 20% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 8.6% decline in the broader market, throughout the period.
With the stock having lost 8.1% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
Check out our latest analysis for Kangji Medical Holdings
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
Even though the Kangji Medical Holdings share price is down over the year, its EPS actually improved. It could be that the share price was previously over-hyped.
It's fair to say that the share price does not seem to be reflecting the EPS growth. But we might find some different metrics explain the share price movements better.
Kangji Medical Holdings managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
SEHK:9997 Earnings and Revenue Growth May 30th 2022We know that Kangji Medical Holdings has improved its bottom line lately, but what does the future have in store? If you are thinking of buying or selling Kangji Medical Holdings stock, you should check out this free report showing analyst profit forecasts.
A Different Perspective
Kangji Medical Holdings shareholders are down 50% for the year (even including dividends), even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 20% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. It's always interesting to track share price performance over the longer term. But to understand Kangji Medical Holdings better, we need to consider many other factors. Even so, be aware that Kangji Medical Holdings is showing 2 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable...
We will like Kangji Medical Holdings better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in Kangji Medical Holdings Limited (HKG:9997) have tasted that bitter downside in the last year, as the share price dropped 51%. That's well below the market decline of 23%. Because Kangji Medical Holdings hasn't been listed for many years, the market is still learning about how the business performs. Furthermore, it's down 20% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 8.6% decline in the broader market, throughout the period.
购买指数基金很容易达到与整体市场回报相匹配的水平。积极投资者的目标是买入表现远远好于大盘的股票--但在这个过程中,他们面临表现不佳的风险。投资者在康基医疗控股有限公司(HKG:9997)去年股价下跌了51%,尝到了苦涩的苦果。这远低于23%的市场跌幅。由于康吉医疗控股已经多年未上市,市场仍在了解该业务的表现。此外,它在大约四分之一的时间里下跌了20%。对于持有者来说,这并不是什么乐趣。当然,在此期间,这一股价走势很可能受到大盘8.6%跌幅的影响。
With the stock having lost 8.1% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
鉴于该公司股价在过去一周下跌了8.1%,我们有必要看看它的业务表现,看看是否有任何危险信号。
Check out our latest analysis for Kangji Medical Holdings
查看我们对康吉医疗控股公司的最新分析
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
虽然有效市场假说继续被一些人传授,但事实证明,市场是过度反应的动态系统,投资者并不总是理性的。评估围绕一家公司的情绪变化的一个有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
Even though the Kangji Medical Holdings share price is down over the year, its EPS actually improved. It could be that the share price was previously over-hyped.
尽管康吉医疗控股的股价在过去一年里有所下降,但其每股收益实际上有所改善。可能是股价之前被过度炒作了。
It's fair to say that the share price does not seem to be reflecting the EPS growth. But we might find some different metrics explain the share price movements better.
公平地说,股价似乎并没有反映出每股收益的增长。但我们可能会发现一些不同的衡量标准可以更好地解释股价走势。
Kangji Medical Holdings managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.
康吉医疗控股去年实现了营收增长,这通常是一个真正的利好消息。由于基本面指标不能很好地解释股价下跌,如果市场反应过度,可能会有机会。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
该公司的收入和收益(随着时间的推移)如下图所示(点击查看具体数字)。
We know that Kangji Medical Holdings has improved its bottom line lately, but what does the future have in store? If you are thinking of buying or selling Kangji Medical Holdings stock, you should check out this free report showing analyst profit forecasts.
我们知道康吉医疗控股最近提高了利润,但未来会是什么样子呢?如果你正在考虑购买或出售康基医疗控股的股票,你应该看看这个免费显示分析师利润预测的报告。
A Different Perspective
不同的视角
Kangji Medical Holdings shareholders are down 50% for the year (even including dividends), even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 20% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Basically, most investors should be wary of buying into a poor-performing stock, unless the business itself has clearly improved. It's always interesting to track share price performance over the longer term. But to understand Kangji Medical Holdings better, we need to consider many other factors. Even so, be aware that Kangji Medical Holdings is showing 2 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable...
康基医疗控股的股东全年下跌50%(即使包括股息),甚至比市场23%的损失还要糟糕。这令人失望,但值得记住的是,整个市场的抛售不会有任何帮助。过去三个月,该公司股价下跌了20%,市场似乎并不认为该公司已经解决了所有问题。基本上,大多数投资者应该对买入表现不佳的股票保持警惕,除非业务本身已经明显改善。跟踪股价的长期表现总是很有趣的。但要更好地理解康基医疗控股,我们还需要考虑许多其他因素。即便如此,请注意,康基医疗控股公司正在展示我们的投资分析中的2个警告信号,其中一条让我们有点不舒服...
We will like Kangji Medical Holdings better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我们看到一些大的内部收购,我们会更喜欢康基医疗控股。在我们等待的时候,看看这个免费最近有大量内幕收购的成长型公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.
请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧